EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck



The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck



Archives of Otolaryngology--Head & Neck Surgery 128(8): 880-885



To determine the safety and efficacy of targeted antitumor therapy with cisplatin/epinephrine injectable gel in patients with advanced squamous cell carcinoma of the head and neck. Two prospective, double-blind, placebo-controlled phase III trials of identical design. Crossover from blinded to open-label phase was permitted for patients with disease progression. Tertiary referral centers in North America and Europe. One hundred seventy-nine intensively pretreated patients with recurrent or refractory squamous cell carcinoma of the head and neck. Cisplatin/epinephrine injectable or placebo gel was administered by direct intratumoral injection; up to 6 weekly treatments. Dose was 0.25 mL of active or placebo gel per cubic centimeter of tumor up to 10 mL total. Patient benefit after local tumor control of the most symptomatic tumor was assessed by patients and physicians using the Treatment Goals Questionnaire. Local tumor response and patient benefit attributable to improvements in tumor-related symptoms. Combined results for the 178 patients with evaluable data in the 2 trials confirmed objective tumor responses in 35 (29%) of 119 patients, including 23 (19%) complete responses achieved with cisplatin/epinephrine gel, vs 1 (2%) of 59 for placebo (P<.001). Tumor response and patient benefit were significantly correlated (P=.006): 47% (17/36) of patients with target tumor responses achieved a rigorously defined benefit based on a prospectively selected treatment goal vs 15% (22/142) of nonresponders. Cisplatin/epinephrine injectable gel reduces tumor burden, ameliorates tumor symptoms, and provides a new therapeutic option for treating patients with squamous cell carcinoma of the head and neck.

(PDF emailed within 0-6 h: $19.90)

Accession: 047726951

Download citation: RISBibTeXText

PMID: 12162764

DOI: 10.1001/archotol.128.8.880



Related references

Treatment of advanced head and neck squamous cell carcinoma with intratumoral cisplatin/epinephrine injectable gel Phase III multicenter studies. European Journal of Cancer 37(Supplement 6): S102, October, 2001

The role of intratumour therapy with electroporation and bleomycin in the management of advanced squamous cell carcinoma of the head and neck. European Journal of Surgical Oncology 31(9): 1029-1035, 2005

Neo-adjuvant chemo- -therapy of advanced squamous-cell head and neck carcinoma A multicenter, phase III, randomized study comparing cisplatin plus 5-fluorouracil with cisplatin plus 5-FU plus recombinant interleukin 2. Cancer Immunology Immunotherapy 47(3): 149-156, 1998

Cisplatin and 5-FU infusions in therapy of advanced squamous cell carcinoma of head and neck in 50 Indian patients. Zhongguo Yao Li Xue Bao 11(3): 288-288, 1990

Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy. European Archives of Oto-Rhino-Laryngology 256(9): 462-465, 1999

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2. Cancer Immunology, ImmunoTherapy 47(3): 149-156, 1998

Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin+5-fluorouracil (5-FU) with cisplatin +5-FU+recombinant interleukin 2. Cancer Immunology, ImmunoTherapy 47(3): 149-156, 1998

Neo-adjuvant chemo-(immuno)-therapy of advanced squamous-cell head and neck carcinoma: A multicenter, phase III, randomized study comparing cisplatin plus 5-fluorouracil (5-FU) with cisplatin plus 5-FU plus recombinant interleukin 2. Cancer Immunology Immunotherapy 47(3): 149-156, 1998

High-dose intra-arterial cisplatin therapy followed by radiation therapy for advanced squamous cell carcinoma of the head and neck. Archives of Otolaryngology--Head & Neck Surgery 127(7): 809-812, 2001

The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 27 Suppl 2: 592-599, 2000

Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. RadioTherapy and Oncology 75(2): 193-196, 2005

The role of neck dissection in the setting of chemoradiation therapy for head and neck squamous cell carcinoma with advanced neck disease. Oral Oncology 48(3): 203-210, 2012

Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head & Neck 38(3): 439-447, 2014

Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma. Oncology 85(5): 290-296, 2014

High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 19(14): 3333-3339, 2001